Boston Scientific stock faces leverage test after negative outlook

Boston Scientific faces a tougher credit backdrop after S&P Global Ratings revised its outlook from stable to negative on Friday, November 6, 2026. The agency affirmed the company's A- issuer and senior unsecured debt ratings and left its A-2 short-term rating unchanged.

Boston Scientific stock traded at 40.91 euros on Lang & Schwarz at 16:31 CET on Wednesday, November 11, 2026. That was 3.23 percent above the 39.63-euro quote in the previous report at 13:20 CET on the same day, a separate comparison from the Xetra daily close.

Franchise pressure slows growth

S&P said Boston Scientific's WATCHMAN and electrophysiology franchises face market and competitive headwinds. WATCHMAN represents 10 percent of revenue, while electrophysiology contributes 16 percent, according to the agency.

The ratings report links the WATCHMAN slowdown to disappointing clinical-trial data and increased competition in left atrial appendage closure. In electrophysiology, competition from Johnson & Johnson, Medtronic and Abbott is weighing on the FARAPULSE franchise.

S&P projects revenue growth of 4.4 percent in 2026 and 9 percent in 2027, well below the mid- to high-teens growth rates achieved in 2024 and 2025. The 2027 forecast includes a full year of Penumbra results.

Penumbra raises execution demands

Boston Scientific plans to acquire Penumbra for 14.5 billion US dollars, with closing expected in early 2027. S&P expects adjusted leverage to rise above 3.6 times after completion, exceeding its 2.5-times downside trigger, and to remain elevated for the following two years.

The company is seeking 500 million US dollars in restructuring savings through 2029. S&P also expects management to limit further acquisitions and share repurchases while integrating Penumbra and reducing leverage.

The agency said the broader cardiovascular and MedSurg portfolio, which represents 74 percent of total revenue, remains diversified and should grow at mid-single-digit rates. A return to a stable outlook would require recovery in WATCHMAN and electrophysiology, smooth integration of Penumbra and leverage below 2.5 times.

Healthcare equities and broader risk appetite can be followed through the S&P 500 market environment.

More news and analyses on Boston Scientific stock remain focused on franchise recovery, Penumbra integration and balance-sheet discipline.